Press release
Investigation announced for Long-Term Investors in NextCure, Inc. (NASDAQ: NXTC)
An investigation on behalf of current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares.
Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NXTC stocks follows a lawsuit filed against NextCure, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NXTC stocks, concerns whether certain NextCure, directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the defendants violated provisions of the Exchange and Securities Acts by misleading investors regarding its leading treatment candidate, NC318. Specifically, the complaint alleges that statements made by Defendants concerning the effectiveness of NC318, the responses observed in patients treated with NC318, and NC318’s potential to treat patients’ refractory to PD-1 therapies were false and misleading.
Those who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in NextCure, Inc. (NASDAQ: NXTC) here
News-ID: 2226044 • Views: …
More Releases from Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders…
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced.
Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term…
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements.
Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:…
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc.
Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for NextCure
Chronic Myelomonocytic Leukaemia Pipeline Analysis (2023) Covering Clinical Tria …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Chronic Myelomonocytic Leukaemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chronic Myelomonocytic Leukaemia Pipeline Insight,…
Chronic Myelomonocytic Leukaemia Pipeline Assessment (2023) Covering Clinical Tr …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Chronic Myelomonocytic Leukaemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chronic Myelomonocytic Leukaemia Pipeline Insight,…
Tumor Immunotherapy Market Report 2023: Detail Research on Global Growth Size, I …
𝑾𝒐𝒓𝒍𝒅𝒘𝒊𝒅𝒆 𝑴𝒂𝒓𝒌𝒆𝒕 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒐𝒇𝒇𝒆𝒓𝒔 𝑼𝒑𝒕𝒐 70% 𝑫𝒊𝒔𝒄𝒐𝒖𝒏𝒕 𝒐𝒏 Tumor Immunotherapy 𝑴𝒂𝒓𝒌𝒆𝒕 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒐𝒏 𝑺𝒊𝒏𝒈𝒍𝒆 𝑼𝒔𝒆𝒓 𝑨𝒄𝒄𝒆𝒔𝒔 𝒂𝒏𝒅 𝑼𝒏𝒍𝒊𝒎𝒊𝒕𝒆𝒅 𝑼𝒔𝒆𝒓 𝑨𝒄𝒄𝒆𝒔𝒔
Tumor Immunotherapy Market 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝟐𝟎𝟐𝟑 𝐢𝐬 𝐜𝐚𝐫𝐞𝐟𝐮𝐥𝐥𝐲 𝐜𝐨𝐧𝐝𝐮𝐜𝐭𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐢𝐧 𝐚 𝐪𝐮𝐚𝐥𝐢𝐭𝐚𝐭𝐢𝐯𝐞 𝐚𝐧𝐝 𝐜𝐨𝐧𝐬𝐢𝐬𝐭𝐞𝐧𝐭 𝐰𝐚𝐲 𝐭𝐨 𝐞𝐧𝐬𝐮𝐫𝐞 𝐚 𝐬𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐨𝐮𝐭𝐜𝐨𝐦𝐞 of Tumor Immunotherapy Market. In addition to identifying, analyzing, and estimating new trends, this research report also examines key industry drivers, challenges, and opportunities in addition to evaluating…
Tumor Immunotherapy Market 2022: Covid-19 Impact, Competitive Landscape, Growth …
Global Tumor Immunotherapy Market Research Report provides a key analysis of the market status of the Tumor Immunotherapy with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe. The report also calculates the market size, Sales, Price, Revenue, Gross Margin, Market Share, cost structure, and growth rate. The report considers the revenue generated from the sales of this Report and technologies…
Investigation announced for Long-Term Investors in shares of NextCure, Inc. (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors of NextCure, Inc..
Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NXTC stocks follows a lawsuit filed against NextCure, Inc. over alleged securities…
Deadline on Nov. 20th coming up in Lawsuit filed for Investors in NextCure, Inc. …
A deadline is coming up on November 20, 2020 in the lawsuit filed for certain investors of NextCure, Inc. (NASDAQ: NXTC).
Investors who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and there are strict and short deadlines running. Deadline: November 20, 2020. NASDAQ: NXTC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for…
